JP2007535912A - 中和エピトープベースの増殖増強性ワクチン - Google Patents

中和エピトープベースの増殖増強性ワクチン Download PDF

Info

Publication number
JP2007535912A
JP2007535912A JP2006547309A JP2006547309A JP2007535912A JP 2007535912 A JP2007535912 A JP 2007535912A JP 2006547309 A JP2006547309 A JP 2006547309A JP 2006547309 A JP2006547309 A JP 2006547309A JP 2007535912 A JP2007535912 A JP 2007535912A
Authority
JP
Japan
Prior art keywords
gdf8
peptide
amino acid
antibody
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006547309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535912A5 (enExample
Inventor
デイビッド イー． ジャンカー，
マーク ディー． コシュラン，
Original Assignee
シェーリング−プラウ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34748944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007535912(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シェーリング−プラウ・リミテッド filed Critical シェーリング−プラウ・リミテッド
Publication of JP2007535912A publication Critical patent/JP2007535912A/ja
Publication of JP2007535912A5 publication Critical patent/JP2007535912A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2006547309A 2003-12-31 2004-12-21 中和エピトープベースの増殖増強性ワクチン Withdrawn JP2007535912A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53371903P 2003-12-31 2003-12-31
PCT/US2004/043125 WO2005066204A2 (en) 2003-12-31 2004-12-21 Neutralizing epitope-based growth enhancing vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011010279A Division JP2011083290A (ja) 2003-12-31 2011-01-20 中和エピトープベースの増殖増強性ワクチン

Publications (2)

Publication Number Publication Date
JP2007535912A true JP2007535912A (ja) 2007-12-13
JP2007535912A5 JP2007535912A5 (enExample) 2008-02-07

Family

ID=34748944

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006547309A Withdrawn JP2007535912A (ja) 2003-12-31 2004-12-21 中和エピトープベースの増殖増強性ワクチン
JP2011010279A Pending JP2011083290A (ja) 2003-12-31 2011-01-20 中和エピトープベースの増殖増強性ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011010279A Pending JP2011083290A (ja) 2003-12-31 2011-01-20 中和エピトープベースの増殖増強性ワクチン

Country Status (21)

Country Link
US (3) US7371726B2 (enExample)
EP (1) EP1699820A2 (enExample)
JP (2) JP2007535912A (enExample)
KR (1) KR20060120229A (enExample)
CN (1) CN1902221A (enExample)
AR (1) AR047345A1 (enExample)
AU (1) AU2004312411B8 (enExample)
BR (1) BRPI0418317A (enExample)
CA (1) CA2551877A1 (enExample)
EC (1) ECSP066683A (enExample)
IL (1) IL176494A0 (enExample)
MX (1) MXPA06007514A (enExample)
NO (1) NO20063478L (enExample)
NZ (1) NZ547593A (enExample)
PE (1) PE20051050A1 (enExample)
RU (1) RU2422460C2 (enExample)
SG (1) SG153874A1 (enExample)
TW (1) TWI357906B (enExample)
UA (1) UA93855C2 (enExample)
WO (1) WO2005066204A2 (enExample)
ZA (1) ZA200605227B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514184C (en) * 2003-01-21 2016-04-12 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) * 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
WO2005066204A2 (en) * 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
JP5335239B2 (ja) 2004-09-30 2013-11-06 マイオスティン・セラピューティクス・プロプライエタリー・リミテッド ミオスタチンアイソフォーム
TW200634156A (en) * 2004-12-30 2006-10-01 Schering Plough Ltd Neutralizing epitope-based growth enhancing vaccine
JP5052517B2 (ja) * 2005-10-06 2012-10-17 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
AU2013231037B2 (en) * 2006-08-03 2016-05-12 Myostin Therapeutics Pty Ltd Myostatin antagonists
JP2009545313A (ja) * 2006-08-03 2009-12-24 オリコ・リミテッド ミオスタチンアンタゴニスト
CA2661836A1 (en) 2006-09-05 2008-03-13 Eli Lilly And Company Anti-myostatin antibodies
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
UY33421A (es) * 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
SG10201506405YA (en) 2010-08-16 2015-10-29 Amgen Inc Polypeptides That Bind Myostatin, Compositions And Methods
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
EP2780368B1 (en) 2011-11-14 2018-01-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
EP2981822B1 (en) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
IL255010B2 (en) 2015-04-15 2024-01-01 Regeneron Pharma Methods of increasing strength and functionality with gdf8 inhibitors
PT3922645T (pt) * 2015-09-15 2025-05-29 Scholar Rock Inc ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
LT3368069T (lt) 2016-06-13 2020-12-10 Scholar Rock, Inc. Miostatino inhibitorių naudojimas, ir kombinuotas gydymas
TW202300168A (zh) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
DK3565592T5 (da) 2017-01-06 2024-09-02 Scholar Rock Inc Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
MA52417A (fr) 2018-03-01 2021-01-06 Regeneron Pharma Procédés de modification de composition corporelle
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507829A (ja) * 1993-03-19 1997-08-12 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−８
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
JP2002504326A (ja) * 1998-02-19 2002-02-12 バイオスター インコーポレイティド 脊椎動物被験体における免疫学的ミオスタチン調節法
JP2002513768A (ja) * 1998-05-06 2002-05-14 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
WO2002094315A2 (en) * 2001-01-04 2002-11-28 Regents Of The University Of Minnesota Myostatin immunoconjugate and its use for immunisation
WO2003027248A2 (en) * 2001-09-26 2003-04-03 Wyeth Antibody inhibitors of gdf-8 and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
CA2014033C (en) * 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
AU2699192A (en) * 1991-10-16 1993-05-21 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
WO1998034639A1 (en) * 1997-02-05 1998-08-13 Biostar Inc. Immunization against endogenous molecules
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US6284882B1 (en) * 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
JP2003506325A (ja) * 1999-07-20 2003-02-18 ファーメクサ エイ／エス Ｇｄｆ−８活性のダウン−レギュレート方法
EP1072680A1 (en) * 1999-07-30 2001-01-31 Pfizer Products Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use
EP1221961A4 (en) 1999-10-13 2004-03-31 Roswell Park Memorial Inst INDUCTION OF A STRONG IMMUNE RESPONSE TO A TUMOR-RELATED SELF-ANTIGEN
US6730306B1 (en) * 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
WO2004052930A2 (en) 2002-12-11 2004-06-24 Pharmexa A/S Targeting single epitopes
WO2004058988A2 (en) 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
WO2005066204A2 (en) * 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
US20060281075A1 (en) * 2004-12-22 2006-12-14 Large Scale Biology Corporation Purification of viruses, proteins and nucleic acids
TW200634156A (en) 2004-12-30 2006-10-01 Schering Plough Ltd Neutralizing epitope-based growth enhancing vaccine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507829A (ja) * 1993-03-19 1997-08-12 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−８
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
JP2002504326A (ja) * 1998-02-19 2002-02-12 バイオスター インコーポレイティド 脊椎動物被験体における免疫学的ミオスタチン調節法
JP2002513768A (ja) * 1998-05-06 2002-05-14 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
WO2002094315A2 (en) * 2001-01-04 2002-11-28 Regents Of The University Of Minnesota Myostatin immunoconjugate and its use for immunisation
WO2003027248A2 (en) * 2001-09-26 2003-04-03 Wyeth Antibody inhibitors of gdf-8 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANTIBODY REFERENCE GUIDE AND CATALOG、［ONLINE］、２００３年５月１日、R&D SYSTEMS INC.、P.14,、イン, JPN7010002220, ISSN: 0001676637 *

Also Published As

Publication number Publication date
NO20063478L (no) 2006-08-28
US7585648B2 (en) 2009-09-08
KR20060120229A (ko) 2006-11-24
UA93855C2 (ru) 2011-03-25
US20050143306A1 (en) 2005-06-30
IL176494A0 (en) 2006-10-05
AU2004312411B2 (en) 2011-11-03
RU2422460C2 (ru) 2011-06-27
PE20051050A1 (es) 2005-12-12
BRPI0418317A (pt) 2007-05-02
TW200526683A (en) 2005-08-16
JP2011083290A (ja) 2011-04-28
ECSP066683A (es) 2006-10-25
TWI357906B (en) 2012-02-11
EP1699820A2 (en) 2006-09-13
MXPA06007514A (es) 2006-08-31
AR047345A1 (es) 2006-01-18
WO2005066204A2 (en) 2005-07-21
US20090311282A1 (en) 2009-12-17
WO2005066204A3 (en) 2005-08-11
CA2551877A1 (en) 2005-07-21
US20080227156A1 (en) 2008-09-18
NZ547593A (en) 2009-09-25
US7892561B2 (en) 2011-02-22
CN1902221A (zh) 2007-01-24
US7371726B2 (en) 2008-05-13
ZA200605227B (en) 2007-03-28
AU2004312411B8 (en) 2011-11-24
RU2006127314A (ru) 2008-02-10
SG153874A1 (en) 2009-07-29
AU2004312411A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
JP2007535912A (ja) 中和エピトープベースの増殖増強性ワクチン
RU2457217C2 (ru) Собачий тимусный стромальный лимфопоэтический белок и его применение
EP2624861B1 (en) Malaria vaccine
CA2593643C (en) A plasmodium vivax hybrid circumsporozoite protein and vaccine
JP2011024590A (ja) 中和エピトープベースの成長増強ワクチン
US20070161545A1 (en) Triple polypeptide complexes
US20230322867A1 (en) Immunogens derived from sars-cov2 spike protein
AU2002339227A1 (en) Triple polypeptide complexes
AU2004234532A1 (en) SPEX compositions and methods of use
US20080286817A1 (en) Novel allergens and treatment
JP2003515340A (ja) マイコプラズマ・ミコイデス亜種ミコイデスＳＣの抗原性タンパク質ＬｐｐＱ、その調製および使用
JP2004534525A (ja) ｕＰＡＲ変異体ｄｅｌ４、ｄｅｌ５およびｄｅｌ４＋５に対する単特異性のポリクローナル抗体の製法並びに診断および治療目的のためのその使用
KR20210033490A (ko) 파라튜버큘로시스에 대한 면역원성 조성물
EP1263955A2 (en) Polypeptides and nucleic acids encoding same
US6800462B2 (en) Production of recombinant proteins in vivo and use for generating antibodies
Dellaratta et al. Characterization of rabbit antisera elicited with human LMP2‐and LMP7‐specific peptides and recombinant proteins
US20050244868A1 (en) Ten-M3 polypeptides and polynucleotides and their methods of use
CN1699422A (zh) 一种牛朊病毒抗体及其制备方法
NZ521434A (en) Novel allergen
KR20110134358A (ko) 면역원성이 증가된 펩티드 항원 및 이를 생산하는 방법
CN1281895A (zh) 一种人线粒体溶质载体蛋白异构体及其编码序列

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101019

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120203

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120216